<http://schema.org/description>
"New drug approvals from Bayer and Actelion threaten United Therapeutics&amp;#39; leadership in treating pulmonary arterial hypertension. Can the company maintain its market share and reward investors?"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2013/11/25/can-united-therapeutics-survive-against-new-compet.aspx>